VCEL Quote, Financials, Valuation and Earnings

ADMA Biologics, Inc. has a net margin of 7.52% compared to Vericel Corp.'s net margin of 27.14%. Vericel Corp.'s return on equity of 4.44% beat ADMA Biologics, Inc.'s return on equity of 58.71%.

Vericel Corp. has a consensus price target of $54.43, signalling upside risk potential of 52.48%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $25.67 which suggests that it could grow by 37.77%. Given that Vericel Corp. has higher upside potential than ADMA Biologics, Inc., analysts believe Vericel Corp. is more attractive than ADMA Biologics, Inc..

Vericel Corp. has a beta of 1.200, which suggesting that the stock is 20.035% more volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.

Vericel Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vericel Corp. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.

Vericel Corp. quarterly revenues are $67.5M, which are smaller than ADMA Biologics, Inc. quarterly revenues of $134.2M. Vericel Corp.'s net income of $5.1M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Vericel Corp.'s price-to-earnings ratio is 151.74x while ADMA Biologics, Inc.'s PE ratio is 23.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vericel Corp. is 7.22x versus 9.96x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Aldeyra Therapeutics, Inc. has a net margin of 7.52% compared to Vericel Corp.'s net margin of --. Vericel Corp.'s return on equity of 4.44% beat Aldeyra Therapeutics, Inc.'s return on equity of -66.61%.

Vericel Corp. has a consensus price target of $54.43, signalling upside risk potential of 52.48%. On the other hand Aldeyra Therapeutics, Inc. has an analysts' consensus of $9.67 which suggests that it could grow by 112.92%. Given that Aldeyra Therapeutics, Inc. has higher upside potential than Vericel Corp., analysts believe Aldeyra Therapeutics, Inc. is more attractive than Vericel Corp..

Vericel Corp. has a beta of 1.200, which suggesting that the stock is 20.035% more volatile than S&P 500. In comparison Aldeyra Therapeutics, Inc. has a beta of 0.831, suggesting its less volatile than the S&P 500 by 16.879%.

Vericel Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Aldeyra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vericel Corp. pays -- of its earnings as a dividend. Aldeyra Therapeutics, Inc. pays out -- of its earnings as a dividend.

Vericel Corp. quarterly revenues are $67.5M, which are larger than Aldeyra Therapeutics, Inc. quarterly revenues of --. Vericel Corp.'s net income of $5.1M is higher than Aldeyra Therapeutics, Inc.'s net income of -$7.7M. Notably, Vericel Corp.'s price-to-earnings ratio is 151.74x while Aldeyra Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vericel Corp. is 7.22x versus -- for Aldeyra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte, Inc. has a net margin of 7.52% compared to Vericel Corp.'s net margin of 14.51%. Vericel Corp.'s return on equity of 4.44% beat Veracyte, Inc.'s return on equity of 2.52%.

Vericel Corp. has a consensus price target of $54.43, signalling upside risk potential of 52.48%. On the other hand Veracyte, Inc. has an analysts' consensus of $47.50 which suggests that it could grow by 10.88%. Given that Vericel Corp. has higher upside potential than Veracyte, Inc., analysts believe Vericel Corp. is more attractive than Veracyte, Inc..

Vericel Corp. has a beta of 1.200, which suggesting that the stock is 20.035% more volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.829, suggesting its more volatile than the S&P 500 by 82.869%.

Vericel Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vericel Corp. pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.

Vericel Corp. quarterly revenues are $67.5M, which are smaller than Veracyte, Inc. quarterly revenues of $131.9M. Vericel Corp.'s net income of $5.1M is lower than Veracyte, Inc.'s net income of $19.1M. Notably, Vericel Corp.'s price-to-earnings ratio is 151.74x while Veracyte, Inc.'s PE ratio is 112.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vericel Corp. is 7.22x versus 6.88x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals, Inc. has a net margin of 7.52% compared to Vericel Corp.'s net margin of -40.15%. Vericel Corp.'s return on equity of 4.44% beat Vanda Pharmaceuticals, Inc.'s return on equity of -16.55%.

Vericel Corp. has a consensus price target of $54.43, signalling upside risk potential of 52.48%. On the other hand Vanda Pharmaceuticals, Inc. has an analysts' consensus of $11.75 which suggests that it could grow by 88.6%. Given that Vanda Pharmaceuticals, Inc. has higher upside potential than Vericel Corp., analysts believe Vanda Pharmaceuticals, Inc. is more attractive than Vericel Corp..

Vericel Corp. has a beta of 1.200, which suggesting that the stock is 20.035% more volatile than S&P 500. In comparison Vanda Pharmaceuticals, Inc. has a beta of 0.687, suggesting its less volatile than the S&P 500 by 31.308%.

Vericel Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vericel Corp. pays -- of its earnings as a dividend. Vanda Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Vericel Corp. quarterly revenues are $67.5M, which are larger than Vanda Pharmaceuticals, Inc. quarterly revenues of $56.3M. Vericel Corp.'s net income of $5.1M is higher than Vanda Pharmaceuticals, Inc.'s net income of -$22.6M. Notably, Vericel Corp.'s price-to-earnings ratio is 151.74x while Vanda Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vericel Corp. is 7.22x versus 1.73x for Vanda Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.